Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure
| Autor: | W. Franklin Peacock, Charles L. Emerman, Marc A. Silver |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
medicine.medical_specialty Acute decompensated heart failure Heart disease Hemodynamics Blood Pressure Placebo Double-Blind Method Intensive care Internal medicine Natriuretic Peptide Brain medicine Humans Aged Heart Failure Nesiritide business.industry General Medicine medicine.disease Surgery Blood pressure Heart failure Emergency Medicine Cardiology Female Natriuretic Agents Hypotension Emergency Service Hospital business medicine.drug |
| Zdroj: | The American Journal of Emergency Medicine. 23:327-331 |
| ISSN: | 0735-6757 |
| Popis: | The Prospective Randomized Outcomes study of Acutely decompensated Congestive heart failure Treated Initially as Outpatients with Nesiritide (PROACTION) trial evaluated the safety of nesiritide administration in the emergency department in patients with decompensated heart failure. Patients (N=237) were treated for at least 12 hours with standard care plus either intravenous nesiritide or placebo. Compared to placebo, nesiritide favorably decreased systolic blood pressure (SBP) in patients with elevated baseline SBP, without negatively impacting patients with lower baseline SBP (SBP,140 mm Hg: nesiritide, -28.7 mm Hg, vs placebo, -8.4 mm Hg [P.001]; SBP, 101-140 mm Hg: nesiritide, -12.3 mm Hg, vs placebo, -5 mm Hg [P.017]; SBP,101 mm Hg: nesiritide, -1.2 mm Hg vs placebo, +16.7 mm Hg [P.03]). Both treatment groups had similar incidences of symptomatic and asymptomatic hypotension. These data demonstrate that early administration of nesiritide in the emergency department is a safe and effective treatment of heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect